Cargando…

Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab

Primary malignant melanoma (MM) of the mediastinum is rare, and there is a lack of consensus regarding the preferred treatment because non-cutaneous MM demonstrates an inferior response to systemic therapy. Herein, we describe the case of a 73-year-old man with MM of the anterior mediastinum with mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakaguchi, Hiroyuki, Tanimoto, Azusa, Sato, Shigeki, Yanagimura, Naohiro, Suzuki, Chiaki, Takumi, Yohei, Nishiyama, Akihiro, Yamashita, Kaname, Takeuchi, Shinji, Ohtsubo, Koshiro, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810244/
https://www.ncbi.nlm.nih.gov/pubmed/34176837
http://dx.doi.org/10.2169/internalmedicine.7452-21
_version_ 1784644210594414592
author Sakaguchi, Hiroyuki
Tanimoto, Azusa
Sato, Shigeki
Yanagimura, Naohiro
Suzuki, Chiaki
Takumi, Yohei
Nishiyama, Akihiro
Yamashita, Kaname
Takeuchi, Shinji
Ohtsubo, Koshiro
Yano, Seiji
author_facet Sakaguchi, Hiroyuki
Tanimoto, Azusa
Sato, Shigeki
Yanagimura, Naohiro
Suzuki, Chiaki
Takumi, Yohei
Nishiyama, Akihiro
Yamashita, Kaname
Takeuchi, Shinji
Ohtsubo, Koshiro
Yano, Seiji
author_sort Sakaguchi, Hiroyuki
collection PubMed
description Primary malignant melanoma (MM) of the mediastinum is rare, and there is a lack of consensus regarding the preferred treatment because non-cutaneous MM demonstrates an inferior response to systemic therapy. Herein, we describe the case of a 73-year-old man with MM of the anterior mediastinum with multiple liver metastases. Even though the size of lesions increased rapidly following diagnosis, nivolumab monotherapy caused remarkable tumor shrinkage. This is the first report of mediastinal MM showing a significant response to nivolumab. We, therefore, suggest that immunotherapy may be one of the treatment options for primary mediastinal MM.
format Online
Article
Text
id pubmed-8810244
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-88102442022-02-15 Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab Sakaguchi, Hiroyuki Tanimoto, Azusa Sato, Shigeki Yanagimura, Naohiro Suzuki, Chiaki Takumi, Yohei Nishiyama, Akihiro Yamashita, Kaname Takeuchi, Shinji Ohtsubo, Koshiro Yano, Seiji Intern Med Case Report Primary malignant melanoma (MM) of the mediastinum is rare, and there is a lack of consensus regarding the preferred treatment because non-cutaneous MM demonstrates an inferior response to systemic therapy. Herein, we describe the case of a 73-year-old man with MM of the anterior mediastinum with multiple liver metastases. Even though the size of lesions increased rapidly following diagnosis, nivolumab monotherapy caused remarkable tumor shrinkage. This is the first report of mediastinal MM showing a significant response to nivolumab. We, therefore, suggest that immunotherapy may be one of the treatment options for primary mediastinal MM. The Japanese Society of Internal Medicine 2021-06-26 2022-01-01 /pmc/articles/PMC8810244/ /pubmed/34176837 http://dx.doi.org/10.2169/internalmedicine.7452-21 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Sakaguchi, Hiroyuki
Tanimoto, Azusa
Sato, Shigeki
Yanagimura, Naohiro
Suzuki, Chiaki
Takumi, Yohei
Nishiyama, Akihiro
Yamashita, Kaname
Takeuchi, Shinji
Ohtsubo, Koshiro
Yano, Seiji
Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
title Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
title_full Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
title_fullStr Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
title_full_unstemmed Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
title_short Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
title_sort mediastinal malignant melanoma markedly shrinking in response to nivolumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810244/
https://www.ncbi.nlm.nih.gov/pubmed/34176837
http://dx.doi.org/10.2169/internalmedicine.7452-21
work_keys_str_mv AT sakaguchihiroyuki mediastinalmalignantmelanomamarkedlyshrinkinginresponsetonivolumab
AT tanimotoazusa mediastinalmalignantmelanomamarkedlyshrinkinginresponsetonivolumab
AT satoshigeki mediastinalmalignantmelanomamarkedlyshrinkinginresponsetonivolumab
AT yanagimuranaohiro mediastinalmalignantmelanomamarkedlyshrinkinginresponsetonivolumab
AT suzukichiaki mediastinalmalignantmelanomamarkedlyshrinkinginresponsetonivolumab
AT takumiyohei mediastinalmalignantmelanomamarkedlyshrinkinginresponsetonivolumab
AT nishiyamaakihiro mediastinalmalignantmelanomamarkedlyshrinkinginresponsetonivolumab
AT yamashitakaname mediastinalmalignantmelanomamarkedlyshrinkinginresponsetonivolumab
AT takeuchishinji mediastinalmalignantmelanomamarkedlyshrinkinginresponsetonivolumab
AT ohtsubokoshiro mediastinalmalignantmelanomamarkedlyshrinkinginresponsetonivolumab
AT yanoseiji mediastinalmalignantmelanomamarkedlyshrinkinginresponsetonivolumab